(1S,2S,4R)-4-(4-((S)-2,3-Dihydro-1H-Inden-1-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidin-7-Yl)-2-(Hydroxymethyl)Cyclopentanol

95%

Reagent Code: #237360
fingerprint
CAS Number 905580-90-7

science Other reagents with same CAS 905580-90-7

blur_circular Chemical Specifications

scatter_plot Molecular Information
Weight 364.44 g/mol
Formula C₂₁H₂₄N₄O₂
inventory_2 Storage & Handling
Storage 2-8°C

description Product Description

This compound is a highly specific inhibitor of JAK (Janus Kinase) enzymes, particularly targeting JAK1 and JAK2, which play crucial roles in cytokine signaling pathways associated with inflammation and immune dysregulation. It is developed for treating immune-related disorders such as rheumatoid arthritis, psoriasis, and psoriatic arthritis.

Its unique structure enables effective activity at low concentrations while minimizing side effects from earlier JAK inhibitors, especially impacts on the blood and liver systems, positioning it as a safer and more efficacious treatment option for chronic conditions.

In pharmaceutical development, this compound is undergoing clinical trials to validate its efficacy and safety across diverse patient populations.

shopping_cart Available Sizes & Pricing

Size Availability Unit Price Quantity
inventory 100mg
10-20 days ฿181,600.00
(1S,2S,4R)-4-(4-((S)-2,3-Dihydro-1H-Inden-1-Ylamino)-7H-Pyrrolo[2,3-D]Pyrimidin-7-Yl)-2-(Hydroxymethyl)Cyclopentanol
No image available

This compound is a highly specific inhibitor of JAK (Janus Kinase) enzymes, particularly targeting JAK1 and JAK2, which play crucial roles in cytokine signaling pathways associated with inflammation and immune dysregulation. It is developed for treating immune-related disorders such as rheumatoid arthritis, psoriasis, and psoriatic arthritis.

Its unique structure enables effective activity at low concentrations while minimizing side effects from earlier JAK inhibitors, especially impacts on the blo

This compound is a highly specific inhibitor of JAK (Janus Kinase) enzymes, particularly targeting JAK1 and JAK2, which play crucial roles in cytokine signaling pathways associated with inflammation and immune dysregulation. It is developed for treating immune-related disorders such as rheumatoid arthritis, psoriasis, and psoriatic arthritis.

Its unique structure enables effective activity at low concentrations while minimizing side effects from earlier JAK inhibitors, especially impacts on the blood and liver systems, positioning it as a safer and more efficacious treatment option for chronic conditions.

In pharmaceutical development, this compound is undergoing clinical trials to validate its efficacy and safety across diverse patient populations.

Mechanism -
Appearance -
Longevity -
Strength -
Storage -
Shelf Life -
Allergen(s) -
Dosage (Range) -
Recommended Dosage -
Dosage (Per Day) -
Recommended Dosage (Per Day) -
Mix Method -
Heat Resistance -
Stable in pH range -
Solubility -
Product Types -
INCI -

Purchase History for

Loading purchase history...